Redefining Dry Eye Disease Management: Emerging Pharmacologic and Device-Based Therapies in the Era of Precision Care: A Narrative Review - PubMed
4 hours ago
- #Precision Care
- #Ocular Surface Inflammation
- #Dry Eye Disease
- Dry eye disease (DED) is a chronic ocular condition characterized by tear film instability and inflammation, affecting comfort, vision, and quality of life.
- Recent advances in DED management include novel pharmacological agents like lifitegrast, improved cyclosporine formulations, and short-term corticosteroids for acute flares.
- New treatments also include secretagogues, biologics, and nasal varenicline spray to stimulate tear production, as well as perfluorohexyloctane for evaporative DED.
- Regenerative approaches such as autologous serum and platelet-rich plasma eye drops are used in severe cases to promote epithelial healing.
- Device-based therapies like thermal pulsation platforms (LipiFlow, iLux, TearCare) and intense pulsed light (IPL) improve meibomian gland function and reduce inflammation.
- Neurostimulator devices and sustained-release drug delivery systems are emerging to enhance tear secretion and treatment adherence.
- Personalized management is key, utilizing point-of-care diagnostics like tear osmolarity testing, MMP-9 assays, and meibography for precise disease classification.
- Long-term care models emphasize maintenance therapy, environmental modifications, digital health tools, and patient education to improve outcomes.